Pharmaceuticals
Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
Anticipated advancements in weight loss, diabetes, oncology, rare conditions
and protein degraders poised to reshape patient care
LONDON, Jan. 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT
2026-01-06 16:21
1987
Ark Biopharmaceutical Receives China Marketing Authorization for Azstarys® for the Treatment of ADHD
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced thatChina's National Medical Products Administration (NMPA) has approved the New Drug Application for Serdexmethylphenidate Chloride and Dexmethylphenidate Hydrochloride Capsules (Azstarys®)...
2026-01-06 14:45
1809
Esco Aster Signs Exosome Clinical cGMP Manufacturing Contract With Shine-On Biomedical For A Novel First-In-Class HLA-G Targeting Exosome Drug Delivery Platform
SINGAPORE, Jan. 6, 2026 /PRNewswire/ -- Esco Aster, a vertically integrated cell and derivatives CRDMO based at JTC LaunchPad Singapore, announced CMC manufacturing support for Shine-On Biomedical's HLA-G targeted exosome program. Shine-On Biomedical sponsored Esco Aster in 2023 for cGMP service...
2026-01-06 12:03
2478
Everest Medicines to Present at the 44th Annual J.P. Morgan Healthcare Conference
SHANGHAI, Jan. 6, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced thatIan Woo, President and Chief Fina...
2026-01-06 07:58
2035
Kelun-Biotech Receives Investigational New Drug Approval for ITGB6-Targeted ADC SKB105 from the NMPA
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) application for SKB105 (also known as CR-003), an internally developed integrin beta-6 (ITGB6)-targeted ant...
2026-01-05 20:00
2201
Sisram Medical Reports Completion of NIFDC Testing for DAXXIFY in China
Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio HONG KONG, Jan. 5, 2026 /PRNewswire/ -- Sisram Medical Ltd (the "Company" or "Sisram", 1696.HK; together with its subsidiaries collectively referred to as the"Group"), a global wellness group off...
2026-01-05 17:36
1851
Kelun-Biotech Announces Breakthrough Therapy Designation Granted in China for Sacituzumab Tirumotecan (sac-TMT) in Combination with Immunotherapy Pembrolizumab for First-Line Treatment of PD-L1-Positive NSCLC
CHENGDU, China, Jan. 5, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company," 6990.HK) today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT, also known as SKB264/MK-2870) (佳泰莱®) in combination wi...
2026-01-05 17:29
2570
Ascletis Announces U.S. FDA IND Clearance for 13-Week Phase II Study of Its Oral Small Molecule GLP-1, ASC30, in Participants with Diabetes
-The Phase II study for diabetes is a 13-week, randomized, double-blind, placebo-controlled and multi-center study to evaluate the efficacy, safety, and tolerability of ASC30 in participants with diabetes. Enrollment is expected to begin in the first quarter of 2026. -ASC30 demonstrated placebo-...
2026-01-05 08:10
2418
Qiming Venture Partners' Insilico Medicine Successfully Lists on Hong Kong Stock Exchange
SHANGHAI, Dec. 31, 2025 /PRNewswire/ -- Insilico Medicine (03696.HK), a global leader in AI-driven drug discovery and a portfolio company of Qiming Venture Partners, today successfully listed on the Hong Kong Stock Exchange (HKEX). The listing marks the largest biotech IPO on theHong Kong stock m...
2025-12-31 08:55
4067
Alphamab Oncology Announces IND Application for a Phase II Clinical Study of HER2 Bispecific ADC Subcutaneous Co-formulation JSKN033 as First-line Treatment of Advanced Cervical Cancer was Officially Accepted by CDE
SUZHOU, China, Dec. 29, 2025 /PRNewswire/ -- Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcutaneous co-formulation consisting of HER2 bispecific antibody-drug conjugate (ADC) and PD-L1 immu...
2025-12-29 13:52
3210
Hakka Medicine Goes Global: Jiaying Pharmaceutical Launches the Global Promotion Plan for Hakka Medicine in Hong Kong
HONG KONG, Dec. 24, 2025 /PRNewswire/ -- Recently, Guangdong Jiaying Pharmaceutical Co., Ltd. held the "First Hakka Medicine Historical and Cultural Symposium" and the "Jiaying Hakka Medicine - Double-ingredient Throat Wind Relief Powder Product Promotion Conference" inHong Kong SAR. Centered on ...
2025-12-24 10:00
1441
TraceLink Wins 2025 Merit Award -- Recognized for Healthcare Innovation for the Third Consecutive Year
TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking its third consecutive year of recognition. The award honors TraceLink's continued leadership in transforming the life sciences and healthcare supply chain through OPUS—its industrial no-code platform tha...
2025-12-22 23:00
1992
Guardant Health Japan receives regulatory approval of Guardant360® CDx liquid biopsy as companion diagnostic for imlunestrant in metastatic or recurrent breast cancer previously treated with endocrine therapy
Guardant360® CDx is the first companion diagnostic to be approved in Japan to identify ESR1 mutations in patients with hormone receptor-positive, HER2-negative breast cancer for treatment with imlunestrant TOKYO, Dec. 22, 2025 /PRNewswire/ -- Guardant Health Japan Corp. today announced that the...
2025-12-22 16:00
2259
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH® CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting Circulating Tumor Cells (CTCs) in the blood to help guide treatment escalation or de-escalation in patients with hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer whose disease progressed after...
2025-12-22 16:00
2105
Fosun International Honored with TVB's Highest Accolade, "Outstanding ESG Award"
HONG KONG, Dec. 22, 2025 /PRNewswire/ -- On 19 December 2025, the TVB ESG Awards 2025 Presentation Ceremony, hosted by Television Broadcasts Limited ("TVB"), was held at the Hong Kong Convention and Exhibition Center. Fosun International was honored with the highest accolade, the "Outstanding ESG...
2025-12-22 09:00
4451
Wong To Yick Unveils Revitalised Official Website
Launching a New No.1 Brand Chapter with Ambassador Joey Yung
Enhanced Authenticity Guidance & Usage Education for Elevated Consumer
Confidence
[High-resolution promotional photo download: Here
2025-12-22 09:00
1583
Precision Medicine Portfolio Update: Illuccix China Phase 3 Study, TLX101-CDx and TLX250-CDx FDA Resubmissions
MELBOURNE, Australia and INDIANAPOLIS, Dec. 22, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today provides a precision medicine portfolio update in relation to: * TLX591-CDx (Illuccix® in approved jurisdictions, 68Ga-PSMA-11): Positive data from Phase ...
2025-12-22 05:40
2081
Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
SUZHOU, China, Dec. 20, 2025 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003, independently developed by the Company, and co-developed with JMT-Bio Technology Co., Ltd., a wholly-owned subsidiary of CSPC P...
2025-12-20 12:54
5078
Neuraxpharm Goes Live with TraceLink MINT to Standardize Real‑Time Data Exchange Across Its Global Supply Chain Network
The European specialty pharmaceutical company establishes a unified digital data foundation to enable future agentic orchestration BOSTON, Dec. 18, 2025 /PRNewswire/ -- TraceLink, the largest end-to-end digital network platform for intelligent orchestration of the supply chain, today announced t...
2025-12-19 00:02
3006
EPS Corporation Selects ArisGlobal's LifeSphere® MultiVigilance
Prominent Japan CRO adopts new safety case processing system to further enhance
compliance, automation, and efficiency
BOSTON, Dec. 18, 2025 /PRNewswire/ -- ArisGloba
2025-12-18 16:27
3334
Week's Top Stories
Most Reposted
Amorepacific Showcases Innovative Technologies at CES 2026
[Picked up by 289 media titles]
2026-01-05 12:14
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
[Picked up by 280 media titles]
2026-01-01 10:00
Radisson Hotel Group Revives Bangkok Icon with Opening of Radisson Hotel Chateau de Bangkok
[Picked up by 280 media titles]
2026-01-06 10:45
Hyundai Motor Group Executive Chair Chung Presents 2026 Vision: Customer-Focused Transformation and AI-Driven Ecosystem Collaboration
[Picked up by 264 media titles]
2026-01-05 09:10
Pepsi & 7UP Team Up with Disney on Zootopia 2, Sparking Fresh Wave of Crossover Youthful Energy
[Picked up by 256 media titles]
2025-12-31 12:53
Most Read
China Daily Launches "China Bound" -- An English-Language Smart-Tourism Service Platform for International Travelers
2026-01-01 17:04
8287
iQIYI LAND Yangzhou to Open on February 8, Marking New Chapter in China's Immersive Entertainment Scene
2026-01-01 10:00
7391